Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Voting Common Stock, par value $0.0001 per share
-
Shares outstanding
-
5,381,598
-
Total 13F shares
-
1,692,019
-
Share change
-
+1,682,949
-
Total reported value
-
$14,651,229
-
Price per share
-
$8.66
-
Number of holders
-
27
-
Value change
-
+$14,572,683
-
Number of buys
-
25
Institutional Holders of Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) as of Q3 2024
As of 30 Sep 2024,
Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,692,019 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, EcoR1 Capital, LLC, Deep Track Capital, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., Vivo Capital, LLC, Woodline Partners LP, BAKER BROS. ADVISORS LP, HHLR ADVISORS, LTD., OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC), and VANGUARD GROUP INC.
This page lists
27
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.